SCHEMBL6895883

SCHEMBL6895883

c1cc2c(cc1CN1CCOCC1)nc1n2CCCN2CCCCC2C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.43
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
POLB P06746 1/20 0.39
L3MBTL3 Q96JM7 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
FLT3 P36888 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6895885 0.97 HRH3 (0.43) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL6896143 0.97 HRH3 (0.43) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL6895812 0.97 HRH3 (0.43) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL6895965 0.94 HRH3 (0.44) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL420061 0.88 HRH3 (0.47) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL7885320 0.83 HRH3 (0.49) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL10012105 0.82 MAPT (0.53) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL6895526 0.82 ALDH1A1 (0.41) HRH3ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL6894034 0.82 HRH3 (0.41) HRH3IRAK4
SCHEMBL6895387 0.79 ALDH1A1 (0.41) HRH3ALDH1A1MAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172350-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-05 US disclosed
US-20120172350-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-05 US disclosed
US-20120172350-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-05 US disclosed
WO-2011031818-A2 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2011-03-17 WO disclosed
WO-2011031816-A2 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2011-03-17 WO disclosed
US-20110065694-A1 Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. 2011-03-17 US disclosed
US-20110065694-A1 Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. 2011-03-17 US disclosed
US-20110065694-A1 Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065694-A1 Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof HRH3, HRH4, HRH2 HRH3 1/4885ALDH1A1 2544/4885MAPT 951/4885
US-20120172350-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 HRH3 1/4885ALDH1A1 2544/4885MAPT 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.